|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | ProANP and NT- proBNP levels to prospectively assess cardia- c function in breast cancer patients treated with cardiotoxic chemotherapy 显示文摘 | Kouloubinis A Kaklamanis L Ziras N | 2007 | Int J Cardio12007，122，3： | 1 |
| 2 | Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non - small cell lung cancer ( NSCLC ) : A multicemer phase Ⅱ study显示文摘 | Kakolyris S Ziras N Vamvakas L | 2006 | Lung Cancer2006，54，3： | 1 |
| 3 | A multieenter phase II tri- al of docetaxel and eapeeitabine as salvage treatment in anthracyeline- and taxane-pretreated patients with metastatic breast cancer 显示文摘 | Karaehaliou N Ziras N Syrigos K | 2012 | Cancer Chemother Pharmaeol2012，70，1： | 1 |
| 4 | Randomised phase-II trial of CAPIRI(capecitabine,irinotecan)plus bevacizumab vs FOLFIRI(folinic acid,5-fluorouracil,irinotecan)plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer(mCRC)显示文摘 | Souglakos J Ziras N Kakolyris S | 2012 | Br J Cancer2012，106，45： | 1 |
| 5 | Phase Ⅰ study of postoperative radiotherapy with concomitant weekly irinotecan,5-fluorouracil and folinic acid in locally advanced rectal cancer显示文摘 | Ziras N Tsoutsou P Koliarakis N | | 0，，： | 1 |
| 6 | Randomised phase-Ⅱ trial of CAPIRI(capecitabine,irinotecan)plus bevacizumab vs FOLFIRI(folinic acid,5-fluorouracil,irinotecan)plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer(mCRC)显示文摘 | SOUGLAKOS J ZIRAS N KAKOLYRIS S | 2012 | Br J Cancer2012，106，3： | 1 |
| 7 | Multicenter phase Ⅱ study of gemcitabine and oxaliplatin (GEMOX) as secondline chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan显示文摘 | Ziras N Potamianou A Varthalitis I | 2006 | Oncology2006，70，2： | 1 |
| 8 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline-and taxane-pretreated patients with metastatic breast cancer显示文摘 | Karachaliou N Ziras N Syrigos K | 2012 | Cancer Chemother Pharmacol2012，70，1： | 1 |
| 9 | A multieenter phase Ⅱ trial of doeetaxel and eapecitabine as salvage treatment in anthracyeline-and taxane-pretreated patients with metastatic breast eaneer显示文摘 | Karachaliou N Ziras N Syrigos K | 2012 | Caneer Chemother Pharmaeol2012，70，1： | 1 |
| 10 | Front - line treatment of advanced breast cancer with docetaxel and epirubicin: a muhicenter phase II study 显示文摘 | Mavroudis D Alexopoulos A Ziras N | 2000 | Ann Oncol2000，11，10： | 1 |
| 11 | Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase Ⅱ study显示文摘 | Kakolyris S Ziras N Vamvakas L | 2006 | Lung Cancer2006，54，3： | 1 |
| 12 | A muhicenter phase II trial of docetaxel and capecitabine as salvage treatment in an- thracycline- and taxane-pretreated patients with metastatic breast cancer 显示文摘 | Karachaliou N Ziras N Syrigos K | 2012 | Cancer Chemother Pharmacol2012，70，： | 1 |
| 13 | Randomised phase-Ⅱ trial of CAPIRI (capecitabine,irinotecan) plus bevacizumab vs FOLFIRI (folinic acid,5-fluorouracil,irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)显示文摘 | Souglakos J Ziras N Kakolyris S | 2012 | Br J Cancer2012，106，3： | 1 |
| 14 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthraeyeline- and taxane-pretreated patients with metastatic breast cancer显示文摘 | Karachaliou N Ziras N Syrigos K | 2012 | Cancer Chemother Pharmacol2012，70，1： | 1 |
| 15 | Gemeitabine plus oxaliplatin combination (gemox regimen) in pretreated patients with advanced non - small cell lung cancer (NSCLC) : a multicenter phase Ⅱ study 显示文摘 | Kakolyfis S Ziras N Vamvakas L | 2006 | Lung Cancer2006，54，3： | 1 |
| 16 | Randomised phase- lI trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first- line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)显示文摘 | Souglakos J Ziras N Kakolyris S | 2012 | Br ] Cancer2012，106，3： | 1 |
| 17 | Randomised phase - II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5 -fluorouracil, irinotecan ) plus bevacizumab as first - line treatment of patients with unresectable/metastatic colorec- tal cancer (mCRC) 显示文摘 | Souglakos J Ziras N Kakolyris S | 2012 | Br J Cancer2012，106，： | 1 |
| 18 | Randomised phase-II trial of CAPIRI (capecitabine,irinotecan) plus bevacizumab vs FOLFIRI (folinic acid,5-fluoroura-cil,irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)显示文摘 | Souglakos J Ziras N Kakolyris S | | 0，，03： | 1 |
| 19 | Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma:a new alternative for an old problem显示文摘 | LYGIDAKIS N J KOSMIDIS P ZIRAS N | 1995 | J Interferon Cytokine Res1995，15，5： | 1 |
| 20 | A multicenter phase Ⅱ trial of docetaxel and capecitabine as salvage treatment in anthracycline-and taxane-pretreated patients with metastatic breast cancer显示文摘 | Karachaliou N Ziras N Syrigos K | 2012 | Cancer C hemother Pharmacol2012，70，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员